Axogen expects at least 24% 2026 revenue growth to at least $279M as Breast accelerates (NASDAQ:AXGN)
· seekingalpha.com
Axogen (AXGN) Q2 2026 earnings call recap: 23% revenue growth, raised FY26 guidance, Breast surge, Avance mix margin pressure, payer updates.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...